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Abstract: Metabolic vulnerability is associated with age-related diseases and concomitant
co-morbidities, which include obesity, diabetes, atherosclerosis and cancer. Most of the health
problems we face today come from excessive intake of nutrients and drugs mimicking dietary
effects and dietary restriction are the most successful manipulations targeting age-related pathways.
Phenotypic heterogeneity and individual response to metabolic stressors are closely related food
intake. Understanding the complexity of the relationship between dietary provision and metabolic
consequences in the long term might provide clinical strategies to improve healthspan. New aspects
of metformin activity provide a link to many of the overlapping factors, especially the way in which
organismal bioenergetics remodel one-carbon metabolism. Metformin not only inhibits mitochondrial
complex 1, modulating the metabolic response to nutrient intake, but also alters one-carbon metabolic
pathways. Here, we discuss findings on the mechanism(s) of action of metformin with the potential
for therapeutic interpretations.
Keywords: diabetes mellitus; energy intake; epigenetics; folic acid; food-drug interactions; food
source; obesity; vitamins B
1. Introduction
Food restriction extends health and lifespan in some models [1], but what nutrients should be
restricted and to what extent? Qualitative changes in the provision of dietary macronutrients induce
metabolic and endocrine adaptations that are clinically relevant to the nutritional status of both,
patients with low food availability and those with a persistent intake of excessive amounts of food [2].
In particular, the relationship between energy and one-carbon (1C) metabolism is extremely sensitive
to food intake [3–6]. We envision that the inclusion of metformin in current strategies promoting
metabolic fitness [7] is in accordance with the clinical response to dietary environment in disease states
and the beneficial effects in metabolically vulnerable cells [8–11]. That is, it is important to revise
what we can learn from metformin users and which are the potential implications. Metformin, as a
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calorie-restriction mimetic drug affecting mitochondrial function, integrates metabolic signals and
the direct effect on folate metabolism may provide therapeutic clues [12–15]. We highlight the effects
of metformin on signaling pathways associated with some of the hallmarks of aging and the likely
beneficial effects in the pathogenesis of comorbidities associated with metabolic diseases (Figure 1).
Whether metformin can be safely used with these new indications remains to be established.
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not inferior to those of a recently approved drug for obesity [16] and the antenatal administration of 
metformin during pregnancy reduces maternal weight gain without effects on neonatal outcomes [17–
19]. Moreover, the Diabetes Prevention Program has found beneficial effects in diabetes prevention 
and a durable weight loss attributable to metformin [20–22]. Cardiovascular benefits are also likely, 
and, when compared to sulfonylurea or insulin therapy, metformin monotherapy is associated with a 
higher reduction in cardiovascular events [23,24]. In addition, the anti-inflammatory actions of 
metformin can be separated from its metabolic effects, and there is ongoing research assessing the role 
of metformin in the prevention and recurrence of breast cancer [25,26].  
All these effects are crucial in preventing disease and promoting health. We discuss here the 
metabolic alterations connecting the metformin response and the function of essential nutrients, 
which emphasize that careful attention to diet might shape clinical strategies [27]. Our arguments 
are framed in the relationship between energy and one-carbon metabolism, reinforced by the 
mechanisms of action proposed for metformin. 
2. One-Carbon Metabolism: Inputs and Outputs  
Folate coenzymes play a crucial role in health and disease and are present in virtually all 
organisms and cell types. Moreover, although controversial, some dietary arguments support the 
addition of folic acid or related compounds to common foods [28–30]. In humans, dietary folic acid is 
reduced to 7,8-dihydrofolate (DHF) and then to 5,6,7,8-tetrahydrofolate (THF) by dihydrofolate 
reductase (DHFR), initiating the folate cycle. Biochemical reactions converge here, using the ability 
of THF to carry 1C units in different oxidation states. Folate coenzymes contain poly-γ-glutamate 
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Metformin is currently used exclusively in the treatment of type 2 diabetes mellitus (T2DM),
but there is potential for additional indications in obesity, inflammatory disorders, cardiovascular
diseases and cancer. For instance, in obese patients without diabetes, the weight loss effects
of metformin are not inferior to those of a recently approved drug for obesity [16] and the
antenatal administration of metformin during pregnancy reduces maternal weight gain without
effects on neonatal outcomes [17–19]. Moreover, the Diabetes Prevention Program has found
beneficial effects in diabetes prevention and a durable weight loss attributable to metformin [20–22].
Cardiovascular benefits are also likely, and, when compared to sulfonylurea or insulin therapy,
metformin monotherapy is associated with a higher reduction in cardiovascular events [23,24].
In addition, the anti-inflammatory actions of metformin can be separated from its metabolic effects,
and there is ongoing research assessing the role of metformin in the prevention and recurrence of
breast cancer [25,26].
All these effects are crucial in preventing disease and promoting health. We discuss here the
metabolic alterations connecting the metformin response and the function of essential nutrients, which
emphasize that careful attention to diet might shape clinical strategies [27]. Our arguments are framed
in the relationship between energy and one-carbon metabolism, reinforced by the mechanisms of
action proposed for metformin.
2. One-Carbon Metabolism: Inputs and Outputs
Folate coenzymes play a crucial role in health and disease and are present in virtually all organisms
and cell types. Moreover, although controversial, some dietary arguments support the addition of
folic acid or related compounds to common foods [28–30]. In humans, dietary folic acid is reduced
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to 7,8-dihydrofolate (DHF) and then to 5,6,7,8-tetrahydrofolate (THF) by dihydrofolate reductase
(DHFR), initiating the folate cycle. Biochemical reactions converge here, using the ability of THF
to carry 1C units in different oxidation states. Folate coenzymes contain poly-γ-glutamate tails
attached to a p-aminobenzoic acid moiety by the activity of folylpolyglutamate synthetase (FPGS),
an essential enzyme that regulates the distribution of different folate forms in cellular compartments
and specific actions in cell proliferation pathways [31,32]. Serine, glycine and methionine are
readily provided in the diet. Serine is oxidized in the mitochondria and transferred to THF by
serine hydroxyl-methyl-transferase (SHMT), resulting in glycine and 5,10-methylene-THF (CH2-THF).
Glycine may be incorporated directly into purine nucleotide bases or glutathione (GSH) and CH2-THF
can be converted to 5-methyl-THF in a reaction catalyzed by methylenetetrahydrofolate reductase
(MTHFR) or 10-formyl-THF according to cellular needs. Of note, serine and glycine may be synthesized
de novo through glycolysis, aldol cleavage (from threonine, in some cells) or reactions involving
demethylation (from choline, betaine, dimethylglycine and sarcosine) [31,32].
The folate cycle, closely linked to the methionine cycle, regulates the availability of methyl
groups (CH3) through the sequential conversion of methionine to S-adenosylmethionine (SAM),
S-adenosylhomocysteine (SAH) and homocysteine. Conversely, in the presence of 5-methyl-THF
(5-mTHF) and methionine synthase, which requires vitamin B12 (cobalamin), methionine can be
regenerated. Transmethylation reactions and intermediate metabolites are crucial to the synthesis of
high-energy molecules, structural macromolecules, thymidine, and purines and to the maintenance of
the cellular redox state and the transsulfuration pathway [33,34]. Dietary vitamins also communicate
bioenergetics and 1C metabolism. For instance, the conversion of homocysteine to cysteine
(transsulfuration pathway) and the synthesis of glutathione require vitamin B6 (pyridoxine) and
vitamin B12 is essential (via the mitochondrial enzyme methylmalonyl-CoA mutase) to form
succinyl-CoA, a key substrate of the citric acid cycle (Figure 2).
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DNA methyltransferase; FAD, flavin adenine dinucleotide; GNMT, glycine N-methyltransferase; 
MAT, aminomethyltransferase; MTHFR, methylenetetrahydrofolate reductase; MTR, 
methyltransferase; SAH, S-adenosylhomocysteine; SAHH, S-adenosylhomocysteine hydrolase; 
SAM, S-adenosylmethionine; SHMT, serine hydroxymethyltransferase; THF, tetrahydrofolate; 
TYMS, thymidylate synthase; UDP, uridine diphosphate. 
The cellular functions that depend on these micronutrients illustrate how important careful 
dietary intake is to avoid deficiencies and how difficult it is to establish clinically based data to be 
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S- ethyltransferase; BS, cystathionine beta-synthase; DHFR, dihydrofolate reductase; DNMT, DNA
methyltransferase; FAD, flavin adenine dinucleotide; GNMT, glycine N-methyltransferase; MAT,
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The cellular functions that depend on these micronutrients illustrate how important careful
dietary intake is to avoid deficiencies and how difficult it is to establish clinically based data to be
used in both the management of disease states and drug treatments. It may appear paradoxical,
but diseases associated with excessive food intake may present deleterious effects that could result
from excess in micronutrients [30]. The challenge is to achieve an adequate nutrient balance in the
different groups within the general population. In this context, several complexities at the organismal
level may be illustrative. For instance, the hepatic effects of diets deficient in choline and methionine
are practically indistinguishable from those observed with methionine rich, high-fat, high-energy
diets. In contrast, the balanced provision of methionine increases healthy lifespan in experimental
models [35–37]. These nutritional observations exemplify the close dependence among regulatory
pathways in energy and one-carbon metabolism and the critical importance of the equilibrium between
inputs and outputs (Figures 2 and 3).
Nutrients 2017, 9, 121 5 of 19
Nutrients 2017, 9, 121 4 of 18 
 
used in both the management of disease states and drug treatments. It may appear paradoxical, but 
diseases associated with excessive food intake may present deleterious effects that could result from 
excess in micronutrients [30]. The challenge is to achieve an adequate nutrient balance in the 
different groups within the general population. In this context, several complexities at the 
organismal level may be illustrative. For instance, the hepatic effects of diets deficient in choline and 
methionine are practically indistinguishable from those observed with methionine rich, high-fat, 
high-energy diets. In contrast, the balanced provision of methionine increases healthy lifespan in 
experimental models [35–37]. These nutritional observations exemplify the close dependence among 
regulatory pathways in energy and one-carbon metabolism and the critical importance of the 
equilibrium between inputs and outputs (Figures 2 and 3). 
 
Figure 3. Schematic representation summarizing the importance of appropriate equilibrium in 
inputs and outputs of one-carbon metabolism. Excessive intake of a given nutrient influences the 
availability of other nutrients and can perturb metabolism with deleterious consequences. 
Understanding the events linking metabolism and diet-dependent pathways may provide crucial 
insight into their role in health and disease. 
3. The Lack of Redundancy between Cytoplasmatic and Mitochondrial One-Carbon Metabolism 
Affects Tissue-Specific Responses to Nutrients 
Deficient or excessive intake of nutrients causes changes in the mitochondrial electron transport 
chain that model the organismal response to the environment. In human cells, the specific forms of 
folate cofactors and the extent of polyglutamylation differ in cytosolic and mitochondrial pools. 
Curiously, 1C metabolism is compartmentalized, and mechanisms controlling the flux of 
components through these compartments are strictly regulated ([38] and references therein). 
Whether mitochondrial dysfunction is a cause or a consequence of disease remains debatable, but it 
appears that mitochondria receive monoglutamate THF, which is polyglutamylated, charged with 
1C units, and later released to the cytosol [39,40], ensuring the correct function of cellular 1C 
metabolism.  
Energy and one-carbon metabolism jointly integrate the cellular nutrient status. Reactions of 
glycine and serine are particularly important connecting nutrition, 1C metabolism and the effects of 
biguanides, as demonstrated in experimental models of glycine auxotrophy. Data in these models 
indicate that the cytoplasmic serine hydroxymethyltransferase (SHMT) isozyme is not essential, but 
glycine biosynthesis requires a different mitochondrial isozyme, which is not reversed by external 
addition of nutrients [41]. Moreover, in the absence of cytoplasmic SHMT, serine donates 1C units 
and formate flows normally to the cytoplasmic THF pool through the activity of mitochondrial 
methylene tetrahydrofolate dehydrogenase (MTHFD), a trifunctional folate-dependent enzyme with 
activity as a CH2-THF dehydrogenase, CH+-THF cyclohydrolase and 10-formyl-THF synthetase. 
Figure 3. Schematic representation summarizing the importance of appropriate equilibrium in inputs
and outputs of one-carbon metabolism. Excessive intake of a given nutrient influences the availability
of other nutrients and can perturb etabolis with deleterious consequences. Understanding the
events linking metabolism and diet-dependent pathways may provide crucial insight into their role in
health and disease.
3. The Lack of Redundancy between Cytoplasmatic and Mitochondrial One-Carbon Metabolism
Affects Tissue-Specific Responses to Nutrients
Deficient or excessive intake of nutrients causes changes in the mitochondrial electron transport
chain that model the organismal response to the environment. In human cells, the specific forms
of folate cofactors and the extent of polyglutamylation differ in cytosolic and mitochondrial pools.
Curiously, 1C metabolism is compartmentalized, and mechanisms controlling the flux of components
through these compartments are strictly regulated ([38] and references therein). Whether mitochondrial
dysfunction is a cause or a consequence of disease remains debatable, but it appears that mitochondria
receive monoglutamate THF, which is polyglutamylated, charged with 1C units, and later released to
the cytosol [39,40], ensuring the correct function of cellular 1C metabolism.
Energy and one-carbon metabolism jointly integrate the cellular nutrient status. Reactions of
glycine and serine are particularly important connecting nutrition, 1C metabolism and the effects of
biguanides, as demonstrated in experimental models of glycine auxotrophy. Data in these models
indicate that the cytoplasmic serine hydroxymethyltransferase (SHMT) isozyme is not essential, but
glycine biosynthesis requires a different mitochondrial isozyme, which is not reversed by external
addition of nutrients [41]. Moreover, in the absence of cytoplasmic SHMT, serine donates 1C units
and formate flows normally to the cytoplasmic THF pool through the activity of mitochondrial
methylene tetrahydrofolate dehydrogenase (MTHFD), a trifunctional folate-dependent enzyme with
activity as a CH2-THF dehydrogenase, CH+-THF cyclohydrolase and 10-formyl-THF synthetase.
Mice without these mitochondrial isozymes (MTHFD2/MTHFD2L) are not viable [42–44]. In addition,
glycine is broken down by the exclusively mitochondrial glycine cleavage syste (GCS) and in this
reaction direction, the electrons are delivered to complex I of the mitochondrial respiratory chain [45].
Metformin affects mitochondrial biology at this point, but information on compensatory pathways is
limited [8,31].
Understanding the transport processes between compartments and how these differences in
cytoplasm and mitochondria control metabolic processes might provide a rationale for treating
metabolic abnormalities. The strictly mitochondrial GCS activities support a model of multiple
carrier-facilitated diffusion of metabolites between cytosol and mitochondria [30]. Because there
is no methionine adenosyltransferase (MAT) activity in mitochondria, putative carriers are also
necessary for the constant transport of SAM from the cytosol to the mitochondria [46]. The relationship
between compartments might also explain the metabolism of choline, which is obtained primarily
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as phosphatidylcholine in the diet. In the liver, choline is a major source of methyl groups through
conversion to betaine (N,N,N-trimethylglycine). The cytosolic betaine hydroxymethyltransferase
(BHMT) generates methionine and N,N-dimethylglycine (DMG), but DMG absolutely requires the
activity of mitochondrial dehydrogenase (DMGDH) to act as a 1C donor in mitochondria. Similarly,
sarcosine (N-methylglycine) can be a 1C donor in the cytoplasm, but in the mitochondria, it requires
sarcosine dehydrogenase (SDH) [47].
Collectively, these multiple regulatory steps indicate essential mechanisms for preventing disease.
Experiments with genetically engineered mice, examining each step, are of limited value to understand
human disease [48], but in humans there are associations between genetic variants and several
diseases [49–54]. Similarly, available data suggest that mitochondrial 1C metabolism is critical for
metabolic adaptations and cell survival in cancer and T cell-mediated (immune) pathologies [55–57].
T cell activation does not increase the expression of proteins related to glycolysis, pentose phosphate
pathway or oxidative phosphorylation. In contrast, T cell activation produces new and specialized
mitochondria characterized by the massive induction of enzymes involved in folate-mediated 1C
metabolism [55], indicating that the mitochondrial and cytosolic pathways for generating and
processing 1C units are not redundant. That is, cytosolic 1C metabolism is insufficient to support
T cell proliferation, cancer cell immortality and excessive metabolic impact when mitochondrial 1C
metabolism is impaired [31,58–62] (Figure 4).
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Mechanisms affecting energy and 1C metabolism are likely linked to cellular biosynthesis, redox
maintenance and epigenetic status. Accurate information on the activities of the aforementioned
enzymes in compl x diseas s might provide clues regarding how nutr tional status or dietary and
pharmacologic manipulations affe t physiological regulation with evident therapeutic opportunities.
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4. The Importance of Drugs and Diets That Modulate Mitochondrial Activity
Mitochondrial function, epigenetic signals and nutrient-sensing pathways are likely combined to
promote health at both the cellular and the organismal levels [63,64]. Drugs and dietary regimens that
directly modulate mitochondrial activity are promising [65].
Mitochondria are not only providers of energy but also of signaling units, and the existence of
mitochondrial-derived peptides (MDPs) suggest the new concept of the existence of mitochondrial
hormones and metabolic regulators [66–68]. Similar to metformin [12,69], targets of these MDPs include
one-carbon metabolism, thiosulfate sulfurtransferase and AMP-activated protein kinase (AMPK),
critical links between nutrients and health. Nutrient sensing is important for the distribution of energy,
and changes in food intake alter metabolic strategies [70,71]. Notably, metformin activates AMPK,
inducing changes in bioactive metabolites connected to transcriptional regulators through as yet
undefined mechanisms [72,73] but probably including an interplay among food intake, metabolism
and mTOR signaling in clinically relevant settings [74,75].
In particular, metabolic aspects in cancer are now a renewed source of potential therapeutic
targets. Cells depleted of mitochondrial DNA identify metabolic vulnerabilities and illustrate that
1C metabolism, serine biosynthesis and transsulfuration are sensitive to mitochondrial dysfunction
and stress [76]. Similarly, cancer cells without the ability to catalyze the conversion of isocitrate
to α-ketoglutarate reveal that perturbing mitochondrial metabolism with metformin may help to
kill cancer cells [77]. The challenge is to learn how to use cell- and tissue-specific variations in the
mitochondrial management of 1C donors and how to interpret the clinical response to manipulations
in nutrient availability. Several lines of evidence indicate that crosstalk between epigenetic signals and
cellular metabolism may be a clinically useful field of research because it represents a mechanism to
convert dietary-induced metabolic changes into stable patterns of altered gene expression [78–81].
5. Is Gene Expression Reprogrammed in Response to Metabolic and Dietary Stimuli Affecting
One-Carbon Metabolism?
Whether epigenetic mechanisms are causally coupled to changes in metabolic phenotypes is
a question posed by epidemiological studies examining extreme nutritional changes during fetal
development [82–85]. It is not surprising, however, to find contradictory data because exposure
windows and conditions are not controlled in documented “experiments” on long-term famine [82–84].
These studies do not reveal the contribution of specific nutrients, but studies in other cohorts associate
defects in energy and one-carbon metabolism in pregnant women with future risk in offspring ([85]
and references therein). Taken together, these data indicate that epigenetic modulation of metabolic
pathways may promote adverse phenotypes in later life [86,87].
In the current context of excessive food intake, it is urgent to understand the potential implications
of modifying epigenetic marks by nutrition and whether diet-induced changes in metabolic or
phenotypic traits may affect future generations. Nutritional, pharmacological and metabolic signals
induce epigenetic drift (i.e., metabolic states correlated with chromatin states), and several epigenetic
marks influence the expression of neighboring genes through generations. It is apparently the feedback
or combination among different epigenetic mechanisms that dynamically configures the chromatin
landscape throughout life [88,89] but DNA methylation alone has strong mechanistic support to
explain modifications by dietary changes. DNA methylation and certain metabolites generated by
mitochondrial respiration interact with transcription factors, suggesting metabolo-epigenetic links
between energy and one-carbon metabolism [90–92]. It is plausible that cellular transcriptional
machinery and chromatin-associated proteins integrate inputs derived from food as part of the
response of living organisms to continuous fluctuations in the availability of energy substrates.
Alterations in genes that encode enzymes affecting chromatin regulation, such as kinases,
acetyltransferases, demethylases and methyltransferases, are common in dietary-related diseases [93].
These enzymes use cellular metabolites as sources of phosphate, acetyl or methyl groups, and interpret
the metabolic state of a specific cell. For instance, the levels of SAM, a methyl donor, SAH and threonine
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alter methylation status through pathways involving acetyl-coA metabolism, and specific dietary
restrictions cause transcriptional and metabolic responses [94,95]. We recently provided an example of
how metformin-driven reduction of acetyl-CoA is sufficient to correct histone H3 acetylation, indicating
that metformin regulates mitonuclear communication and the cellular epigenetic landscape. These
data may result in knowledge that can be applied to metabolo-epigenetic strategies for prevention
or therapy [96]. Future research will ascertain how dietary manipulations and synthetic epigenetic
modifiers contribute to DNA methylation and how plastic the genome is to dietary changes. It is also
important to establish what magnitude of metabolic stimuli is required to produce appreciable changes
and whether epigenetic changes can be reversed.
6. The Ability of Metformin to Target One-Carbon Metabolism: Perspectives in Clinical
Practice Outcomes
The dietary inputs associated with the folate and methionine cycles support cellular integrity
and health, but there is some risk in manipulating bioactive elements in the absence of well-proven
associations between consumption and disease. This probably explains why nutritional manipulation
is not incorporated into clinical practice against cancer, but we should not forget that the action of B
vitamins led to the discovery of folate antagonists as a major class of cancer chemotherapy agents [97]
and that restriction in some nutrients negatively affect tumor formation in mice [98].
The multi-faceted activity of metformin and its likely interconnected mechanisms of action
are relevant to potential applications in diseases characterized by mitochondrial dysfunction,
gene deregulation and failure in metabolic homeostasis [99–103]. The global metabolic impact
of metformin and the generated energetic stress suggest a strong association with the overall
management of food intake. Metformin stimulates glucose uptake by muscle, inhibits hepatic
gluconeogenesis and stimulates AMPK through effects in NADH ubiquinone oxidoreductase, the
first component of the electron transport chain. Other putative actions with dietary associations
include AMPK-independent signaling through glucagon-dependent cyclic AMP and the inhibition
of mitochondrial glycerophosphate dehydrogenase [103–105]. These findings on metformin action
suggest an approach for treating metabolic diseases not restricted to the field of diabetes.
It could be argued that drugs reducing insulin levels may reduce cancer risk, and drugs that
increase circulating insulin may increase cancer risk, but the effects of metformin in cancer cells seem
specific, preventing the boost in glycolytic intermediates, decreasing citric acid cycle intermediates, and
depleting the cellular glutathione content [106]. Moreover, metformin impairs one-carbon metabolism
in a manner similar to drugs that target folate-related enzymes and have long been used to treat
inflammatory diseases and cancer [8,12,106–109]. Efforts to clinically address this issue remain
incomplete and difficult to interpret because heterogeneity in metformin response is considerable
and only partially explained by genetic and nutritional factors. Metformin pharmacodynamics and
pharmacokinetics have been reviewed recently ([110] and references therein). Current formulations
have a bioavailability of ~50% (approximately 40% is absorbed in the duodenum and proximal
jejunum, and ~10% in the ileum and colon). Unabsorbed drug is eliminated in the feces, and
metformin circulates in the plasma unbound and without transformation until cleared by the kidneys.
Metformin is a hydrophilic molecule requiring specific mechanisms of transport, primarily organic
cation transporters (OCT). Briefly, plasma membrane monoamine transporter (PMAT) and OCT3
contribute to gastrointestinal uptake, and OCT1 may be responsible for transport into the interstitial
fluid of the intestine. OCT1, OCT3 and multidrug and toxin extrusion proteins (MATE) are expressed
on the basolateral membrane of hepatocytes. In the kidney, metformin is taken up into renal epithelial
cells by OCT2 and excreted into the urine via MATE1 and MATE2. OCT1 and PMAT may contribute
to metformin reabsorption. Genetic variants of these and other transporters may be important to
explain the therapeutic action of metformin, the high inter-individual variability in gastrointestinal
tolerance and drug–drug interactions [111–114]. It would be useful to ascertain whether these genetic
variants could have predictive value in patients before they take the drug [115], but genetics alone
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frequently fail to explain phenotypes. In this context, we foresee that considering metformin for
non-diabetic indications is an example of the value of applying metabolomics to useful clinical
research. The next task is connecting energy and one-carbon metabolism to physiology, describing
heterogeneous phenotypes and defining the role of nutrition in the response to drug treatment.
7. The One-Carbon Cycle in Metformin Users and Potential Adverse Effects
We believe that metformin is best described as an “antimetabolite” drug, and, as such, several
deleterious effects might be expected among long-term metformin users. Trials to ascertain these effects
are scarce, and data are frequently contradictory, but people at risk of deficiency in one-carbon-related
metabolites include vegans, vegetarians, pregnant women, breastfeeding women, the elderly and
patients with anemia or poor renal function [116].
There is no evidence of risk in humans from taking metformin during pregnancy, but this issue
requires attention [17]. Folate deficiency in metformin users is rare, but a decrease in serum and red
blood cell (RBC) folate concentration is common [117]. It is difficult to ascertain the effect of folate
fortification in some foods due to discrepancies in results [118] and the lack of data regarding folate
bioavailability in metformin users [34,119]. Favoring the consumption of foods that are endogenously
high in folates is probably reminiscent of decades using folates with cytotoxic agents, but this empirical
practice requires caution. For instance, lessons from a prospective study in rural India indicate
that normal/high folate concentrations associated with deficiencies in vitamin B12, attributable to
a lacto-vegetarian diet combined with folic acid supplementation, may be associated with a higher
risk of insulin resistance in the offspring [120]. This is relevant because metformin might facilitate the
mechanism known as “methyl folate trap”, which acts on the regulation of the methionine/folate cycle
and cysteine oxidation [121]. According to this concept, although only demonstrated in pernicious
anemia, the cell would mistakenly interpret vitamin B12 deficiency as a lack of methionine, and will
divert the remaining folate away from DNA biosynthesis towards the methylation of homocysteine to
methionine, building up 5 methyl THF that the cell will not be able to use [121].
The relationship between vitamin B12 deficiency and metformin treatment has been studied since
the beginning of the 1970s with some clinical confusion likely related to the extreme heterogeneity
among studies [122–124]. Among metformin users, a slight reduction in serum vitamin B12
concentrations is common, but some studies have reported contradictory results indicating that
metformin has no effect or even might improve vitamin B12 metabolism [125–127]. No mechanism
has been proposed and the issue requires further research but there is probably no clinical relevance in
these observations as discussed below. Moreover, the possible benefits of vitamin B12 supplements in
metformin users have not been assayed and the notion of causality is complicated because diabetes
and obesity are also associated with vitamin B12 reductions [128].
Metformin does not significantly increase blood lactate levels, but we are probably depriving
some patients from potential benefits based on the putative risk of lactic acidosis [129]. After 70 years
of real-world clinical experience, the incidence of lactic acidosis is mostly based in anecdotal reports.
However, caution is important in individuals with reduced metformin clearance (i.e., poor renal
function), reduced lactate clearance (i.e., impaired hepatic metabolism), and/or increased lactate
production (i.e., sepsis or reduced tissue perfusion). Advanced age may also increase risk because
of age-related decline in renal function and increased risk for acute renal failure (i.e., dehydration),
drug–drug interactions and other medical conditions. Moreover, elderly patients with type 2 diabetes
are independently at greater risk for hyperlactatemia and have a reduced threshold for the development
of lactic acidosis in response to a secondary event [130].
The most frequent adverse effects are gastrointestinal in nature: diarrhea, nausea, and to a lesser
extent, vomiting, flatulence or heartburn. Of note, in randomized controlled trials, similar effects
are found in the placebo group, indicating potential bias [131]. Those patients without preexisting
gastrointestinal conditions are apparently free of these effects, but it is not uncommon that some
patients decline using metformin [112,113]. Metformin response and tolerance are intrinsically
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associated with the gut and the intake of nutrients [132]. Metformin could increase serum glucagon-like
peptide 1 concentration by increasing its secretion from L cells, distributed throughout the intestine,
and/or by reducing its breakdown by dipeptidyl peptidase-4 in the intestinal mucosa and portal
system [133]. Curiously, serotonin and histamine release from the intestine are associated with
similar effects (nausea, vomiting, increased gut motility and diarrhea). It is possible that metformin
inhibits diamine oxidase, which is highly expressed in enterocytes and responsible for the metabolism
of these gut peptides [134]. Metformin might also disrupt the enterohepatic circulation of bile
salts, predominantly through reduced ileal absorption and osmotic effects facilitating diarrhea [135].
Finally, the gut microbiome is considered an environmental factor contributing to the development of
metabolic diseases and a possible target of metformin. A reduction in butyrate-producing bacteria and
an increase in opportunistic pathogens are common in type 2 diabetes and could potentially influence
gastrointestinal tolerance [136–138].
8. Measuring the Impact of Folate-Related Deficiencies in the Clinical Setting: Potential for
Targeted Metabolomics
Results from immunoassays in clinical laboratories are difficult to interpret and limited by
the availability of reagents and automated biochemistry platforms. Methodological constraints,
confounding factors, and poor inter-laboratory reproducibility are common pitfalls [139–141].
Consequently, the picture obtained when exploring folate metabolism is partial at best. For instance,
total circulating B12 in serum is unreliable in some clinical conditions and practically useless as
a method to detect true, functional B12 deficiency [142]. Most (80%) of B12 is bound in serum to
haptocorrin, and a variable proportion (5%–20%) is bound to transcobalamin II and ready for tissue
uptake (holotranscobalamin). Measuring in the same batch serum holotranscobalamin, homocysteine
and/or methylmalonic acid can mitigate limitations [125,143]. Some pitfalls were made evident in a
large cohort of participants enrolled in the REasons for Geographic and Racial Differences in Stroke
(REGARDS) study [144]. The proportion of participants with low serum B12 concentration was exactly
the same (2%; not clinically evident) in participants without diabetes and in long-term metformin
users with diabetes. However, serum B12 concentrations were lower in metformin users than in those
who did not use metformin. Curiously, metformin users were less likely to have taken multivitamins
(6–25 µg of vitamin B12 per dose), and multivitamin users had a significantly higher serum B12
concentration compared to those who did not take multivitamins [144]. A longitudinal study to
assess the impact of metformin is warranted, but it appears that laboratory biomarkers do not add
significantly to clinical decisions and that dietary advice might contribute to better management of
metformin users [145].
Similarly, measurement of serum folate with standard immunoassays is accompanied by possible
errors in interpretation. For instance, obesity appears to be associated with decreased serum (measuring
recent folate intake) but also with increased RBC folate (measuring a long term intake) concentrations
compared with lean subjects. The association is plausible but the presence of obesity-associated
metabolic disturbances hampers further interpretations [146]. It was recently clarified that folate
measurements in serum and in RBC display similar performance in assessing folate status [147].
The use of both measures generates higher and unnecessary costs, but the RBC folate assay is less
likely to provide falsely normal levels attributable to dietary behavior or recent supplements [147].
The observation that metformin is associated with a slight, but sometimes significant, raise in
homocysteine and/or decrease in folate needs careful consideration, but there is no sufficient evidence
to recommend folic acid supplements to metformin users [148,149].
It remains unknown how nutritional manipulations may affect the complex relationships among
metabolites involved in the 1C cycle, but studies in women with seasonal variations in nutrient intake
highlight the need to measure all metabolites and cofactors [150,151]. Analytical platforms should
provide measurements of different folate species, especially 5-methyltetrahydrofolate as the active
1C donor [150,151]. Specifically, it is important to confirm data suggesting that levels of maternal
Nutrients 2017, 9, 121 11 of 19
one-carbon metabolites at conception influence DNA methylation in the early embryo and that
offspring methylation correlates with the paternal somatic methylation pattern [152]. This effort implies
better tools for measuring intermediate metabolites either side of the involved reactions [153,154].
Targeted metabolomics may help in pursuing a better interpretation. In this context, ultra-high
pressure liquid chromatography coupled to an electrospray ionization source and a triple-quadrupole
mass spectrometer is an affordable choice to quantitatively examine the methionine/folate bi-cyclic
1C metabolome [155]. This method has been used to explore the activation of methylogenesis in
some models. This essential function of 1C metabolism provides a labile pool of methyl groups
required for successfully establishing and maintaining the DNA methylation imprint [155]. A similar
approach has been used to explore energy metabolism with a simple and rapid method based on
gas chromatography coupled to quadrupole time-of-flight mass spectrometry and an electron impact
source [156]. The accurate and simultaneous measurement of selected metabolites facilitates the
understanding of metabolic responses to changing environmental factors and has the potential for
searching quantitative biomarkers of disease and signals indicating the ability of drugs to restore
cellular homeostasis [157]. In addition, this analytical approach may serve to assess the expected
toxicity in potential applications for metformin employed in oncology at doses notably higher than
those used chronically in the management of diabetes [8].
9. Conclusions
Metformin users may provide data on the effect of nutrients in health and disease.
There is growing evidence demonstrating the multiple protective effects of metformin against
obesity-associated diseases, a major challenge to global public health. Some findings support the
idea that metformin mediates the mitochondrial response to excessive food intake and the effect of
different micronutrients. In particular, the mechanism of action of metformin involves effects on both
energy and one-carbon metabolism and suggests novel strategies that involve the combination of
lifestyle modification with pharmacotherapy. The concept is more important in individuals whose risk
factors are not reduced by dietary interventions and dietary regimens in metformin users may provide
valuable information. We envision that several analytical approaches in the field of metabolomics
can provide diagnostic indicators on multiple metabolic aspects and may ascertain the effects of
nutrient intake. Accordingly, it is especially relevant to assess the role of significant nutrients, such as
serine, glycine, methionine, folic acid or other B vitamins, affecting one-carbon metabolism. Efforts
to repurpose metformin, the first choice as an oral treatment of type 2 diabetes, as an antimetabolite
drug, reinforce the interest in understanding food and drug interactions and the expected toxic effects
caused by a change in dose range.
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30. Patel, K.R.; Sobczyńska-Malefora, A. The adverse effects of an excessive folic acid intake. Eur. J. Clin. Nutr.
2016. [CrossRef] [PubMed]
31. Locasale, J.W. Serine, glycine and one-carbon units: Cancer metabolism in full circle. Nat. Rev. Cancer 2013,
13, 572–583. [CrossRef] [PubMed]
32. Mattaini, K.R.; Sullivan, M.R.; Vander Heiden, M.G. The importance of serine metabolism in cancer. J. Cell Biol.
2016, 214, 249–257. [CrossRef] [PubMed]
33. Kopp, M.; Morisset, R.; Koehler, P.; Rychlik, M. Stable Isotope Dilution Assays for Clinical Analyses of
Folates and Other One-Carbon Metabolites: Application to Folate-Deficiency Studies. PLoS ONE 2016, 11,
E0156610. [CrossRef] [PubMed]
34. Mönch, S.; Netzel, M.; Netzel, G.; Ott, U.; Frank, T.; Rychlik, M. Folate bioavailability from foods rich in
folates assessed in a short term human study using stable isotope dilution assays. Food Funct. 2015, 6,
242–248. [CrossRef] [PubMed]
35. Mato, J.M.; Martinez-Chantar, M.L.; Lu, S.C. Methionine metabolism and liver disease. Annu. Rev. Nutr.
2008, 28, 273–293. [CrossRef] [PubMed]
36. Pacana, T.; Cazanave, S.; Verdianelli, A.; Patel, V.; Min, H.K.; Mirshahi, F.; Quinlivan, E.; Sanyal, A.J.
Dysregulated Hepatic Methionine Metabolism Drives Homocysteine Elevation in Diet-Induced Nonalcoholic
Fatty Liver Disease. PLoS ONE 2015, 10, E0136822. [CrossRef] [PubMed]
37. Lee, B.C.; Kaya, A.; Gladyshev, V.N. Methionine restriction and life-span control. Ann. N. Y. Acad. Sci. 2016,
1363, 116–124. [CrossRef] [PubMed]
38. Tibbetts, A.S.; Appling, D.R. Compartmentalization of Mammalian folate-mediated one-carbon metabolism.
Annu. Rev. Nutr. 2010, 30, 57–81. [CrossRef] [PubMed]
39. Lin, B.F.; Huang, R.F.; Shane, B. Regulation of folate and one-carbon metabolism in mammalian cells. III. Role
of mitochondrial folylpoly-gamma-glutamate synthetase. J. Biol. Chem. 1993, 268, 21674–21679. [PubMed]
40. Lawrence, S.A.; Titus, S.A.; Ferguson, J.; Heineman, A.L.; Taylor, S.M.; Moran, R.G. Mammalian
mitochondrial and cytosolic folylpolyglutamate synthetase maintain the subcellular compartmentalization
of folates. J. Biol. Chem. 2014, 289, 29386–29396. [CrossRef] [PubMed]
41. McCarthy, E.A.; Titus, S.A.; Taylor, S.M.; Jackson-Cook, C.; Moran, R.G. A mutation inactivating the
mitochondrial inner membrane folate transporter creates a glycine requirement for survival of Chinese
hamster cells. J. Biol. Chem. 2004, 279, 33829–33836. [CrossRef] [PubMed]
42. Christensen, K.E.; Patel, H.; Kuzmanov, U.; Mejia, N.R.; MacKenzie, R.E. Disruption of the mthfd1 gene
reveals a monofunctional 10-formyltetrahydrofolate synthetase in mammalian mitochondria. J. Biol. Chem.
2005, 280, 7597–7602. [CrossRef] [PubMed]
Nutrients 2017, 9, 121 14 of 19
43. Field, M.S.; Kamynina, E.; Stover, P.J. MTHFD1 regulates nuclear de novo thymidylate biosynthesis and
genome stability. Biochimie 2016, 126, 27–30. [CrossRef] [PubMed]
44. Giardina, G.; Brunotti, P.; Fiascarelli, A.; Cicalini, A.; Costa, M.G.; Buckle, A.M.; di Salvo, M.L.; Giorgi, A.;
Marani, M.; Paone, A.; et al. How pyridoxal 5′-phosphate differentially regulates human cytosolic and
mitochondrial serine hydroxymethyltransferase oligomeric state. FEBS J. 2015, 282, 1225–1241. [CrossRef]
[PubMed]
45. Hampson, R.K.; Barron, L.L.; Olson, M.S. Regulation of the glycine cleavage system in isolated rat liver
mitochondria. J. Biol. Chem. 1983, 258, 2993–2999. [PubMed]
46. Horne, D.W.; Holloway, R.S.; Wagner, C. Transport of S-adenosylmethionine in isolated rat liver mitochondria.
Arch. Biochem. Biophys. 1997, 343, 201–206. [CrossRef] [PubMed]
47. O’Donoghue, N.; Sweeney, T.; Donagh, R.; Clarke, K.J.; Porter, R.K. Control of choline oxidation in rat kidney
mitochondria. Biochim. Biophys. Acta 2009, 1787, 1135–1139. [CrossRef] [PubMed]
48. Peng, L.; Dreumont, N.; Coelho, D.; Guéant, J.L.; Arnold, C. Genetic animal models to decipher the
pathogenic effects of vitamin B12 and folate deficiency. Biochimie 2016, 126, 43–51. [CrossRef] [PubMed]
49. Cheng, T.Y.; Makar, K.W.; Neuhouser, M.L.; Miller, J.W.; Song, X.; Brown, E.C.; Beresford, S.A.; Zheng, Y.;
Poole, E.M.; Galbraith, R.L.; et al. Folate-mediated one-carbon metabolism genes and interactions with
nutritional factors on colorectal cancer risk: Women’s Health Initiative Observational Study. Cancer 2015,
121, 3684–3691. [CrossRef] [PubMed]
50. Pangilinan, F.; Molloy, A.M.; Mills, J.L.; Troendle, J.F.; Parle-McDermott, A.; Kay, D.M.; Browne, M.L.;
McGrath, E.C.; Abaan, H.O.; Sutton, M.; et al. Replication and exploratory analysis of 24 candidate risk
polymorphisms for neural tube defects. BMC Med. Genet. 2014, 15, 102. [CrossRef] [PubMed]
51. Krishna, S.M.; Dear, A.; Craig, J.M.; Norman, P.E.; Golledge, J. The potential role of homocysteine mediated
DNA methylation and associated epigenetic changes in abdominal aortic aneurysm formation. Atherosclerosis
2013, 228, 295–305. [CrossRef] [PubMed]
52. De Vilbiss, E.A.; Gardner, R.M.; Newschaffer, C.J.; Lee, B.K. Maternal folate status as a risk factor for autism
spectrum disorders: A review of existing evidence. Br. J. Nutr. 2015, 114, 663–672. [CrossRef] [PubMed]
53. Martorell, L.; Segués, T.; Folch, G.; Valero, J.; Joven, J.; Labad, A.; Vilella, E. New variants in the mitochondrial
genomes of schizophrenic patients. Eur. J. Hum. Genet. 2006, 14, 520–528. [CrossRef] [PubMed]
54. Vilella, E.; Virgos, C.; Murphy, M.; Martorell, L.; Valero, J.; Simó, J.M.; Joven, J.; Fernández-Ballart, J.; Labad, A.
Further evidence that hyperhomocysteinemia and methylenetetrahydrofolate reductase C677T and A1289C
polymorphisms are not risk factors for schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2005, 29,
1169–1174. [CrossRef] [PubMed]
55. Ron-Harel, N.; Santos, D.; Ghergurovich, J.M.; Sage, P.T.; Reddy, A.; Lovitch, S.B.; Dephoure, N.;
Satterstrom, F.K.; Sheffer, M.; Spinelli, J.B.; et al. Mitochondrial Biogenesis and Proteome Remodeling
Promote One-Carbon Metabolism for T Cell Activation. Cell Metab. 2016, 24, 104–117. [CrossRef] [PubMed]
56. DeBerardinis, R.J.; Lum, J.J.; Hatzivassiliou, G.; Thompson, C.B. The biology of cancer: Metabolic
reprogramming fuels cell growth and proliferation. Cell Metab. 2008, 7, 11–20. [CrossRef] [PubMed]
57. Sullivan, L.B.; Gui, D.Y.; Hosios, A.M.; Bush, L.N.; Freinkman, E.; Vander Heiden, M.G. Supporting aspartate
biosynthesis is an essential function of respiration in proliferating cells. Cell 2015, 162, 552–563. [CrossRef]
[PubMed]
58. Fan, J.; Ye, J.; Kamphorst, J.J.; Shlomi, T.; Thompson, C.B.; Rabinowitz, J.D. Quantitative flux analysis reveals
folate-dependent NADPH production. Nature 2014, 510, 298–302. [CrossRef] [PubMed]
59. Ye, J.; Fan, J.; Venneti, S.; Wan, Y.W.; Pawel, B.R.; Zhang, J.; Finley, L.W.; Lu, C.; Lindsten, T.; Cross, J.R.
Serine catabolism regulates mitochondrial redox control during hypoxia. Cancer Discov. 2014, 4, 1406–1417.
[CrossRef] [PubMed]
60. Piskounova, E.; Agathocleous, M.; Murphy, M.M.; Hu, Z.; Huddlestun, S.E.; Zhao, Z.; Leitch, A.M.;
Johnson, T.M.; DeBerardinis, R.J.; Morrison, S.J. Oxidative stress inhibits distant metastasis by human
melanoma cells. Nature 2015, 527, 186–191. [CrossRef] [PubMed]
61. Jain, M.; Nilsson, R.; Sharma, S.; Madhusudhan, N.; Kitami, T.; Souza, A.L.; Kafri, R.; Kirschner, M.W.;
Clish, C.B.; Mootha, V.K. Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation.
Science 2012, 336, 1040–1044. [CrossRef] [PubMed]
Nutrients 2017, 9, 121 15 of 19
62. Maddocks, O.D.; Berkers, C.R.; Mason, S.M.; Zheng, L.; Blyth, K.; Gottlieb, E.; Vousden, K.H. Serine
starvation induces stress and p53-dependent metabolic remodelling in cancer cells. Nature 2013, 493, 542–546.
[CrossRef] [PubMed]
63. Finkel, T. The metabolic regulation of aging. Nat. Med. 2015, 21, 1416–1423. [CrossRef] [PubMed]
64. Sena, L.A.; Chandel, N.S. Physiological roles of mitochondrial reactive oxygen species. Mol. Cell 2012, 48,
158–167. [CrossRef] [PubMed]
65. Suliman, H.B.; Piantadosi, C.A. Mitochondrial Quality Control as a Therapeutic Target. Pharmacol. Rev. 2016,
68, 20–48. [CrossRef] [PubMed]
66. Guo, B.; Zhai, D.; Cabezas, E.; Welsh, K.; Nouraini, S.; Satterthwait, A.C.; Reed, J.C. Humanin peptide
suppresses apoptosis by interfering with Bax activation. Nature 2003, 423, 456–461. [CrossRef] [PubMed]
67. Lee, C.; Zeng, J.; Drew, B.G.; Sallam, T.; Martin-Montalvo, A.; Wan, J.; Kim, S.J.; Mehta, H.; Hevener, A.L.;
de Cabo, R.; et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces
obesity and insulin resistance. Cell Metab. 2015, 21, 443–454. [CrossRef] [PubMed]
68. Quirós, P.M.; Mottis, A.; Auwerx, J. Mitonuclear communication in homeostasis and stress. Nat. Rev. Mol.
Cell Biol. 2016, 17, 213–226. [CrossRef] [PubMed]
69. Morton, N.M.; Beltram, J.; Carter, R.N.; Michailidou, Z.; Gorjanc, G.; McFadden, C.; Barrios-Llerena, M.E.;
Rodriguez-Cuenca, S.; Gibbins, M.T.; Aird, R.E.; et al. Genetic identification of thiosulfate sulfurtransferase
as an adipocyte-expressed antidiabetic target in mice selected for leanness. Nat. Med. 2016, 22, 771–779.
[CrossRef] [PubMed]
70. Fitzgibbons, T.P.; Czech, M.P. Emerging evidence for beneficial macrophage functions in atherosclerosis and
obesity-induced insulin resistance. J. Mol. Med. 2016, 94, 267–275. [CrossRef] [PubMed]
71. Hardie, D.G.; Schaffer, B.E.; Brunet, A. AMPK: An Energy-Sensing Pathway with Multiple Inputs and
Outputs. Trends Cell Biol. 2016, 26, 190–201. [CrossRef] [PubMed]
72. Beltrán-Debón, R.; Rodríguez-Gallego, E.; Fernández-Arroyo, S.; Senan-Campos, O.; Massucci, F.A.;
Hernández-Aguilera, A.; Sales-Pardo, M.; Guimerà, R.; Camps, J.; Menendez, J.A.; et al. The acute impact of
polyphenols from Hibiscus sabdariffa in metabolic homeostasis: An approach combining metabolomics and
gene-expression analyses. Food Funct. 2015, 6, 2957–2966. [CrossRef] [PubMed]
73. Liu, C.; Wu, J.; Zhu, J.; Kuei, C.; Yu, J.; Shelton, J.; Sutton, S.W.; Li, X.; Yun, S.J.; Mirzadegan, T.; et al. Lactate
inhibits lipolysis in fat cells through activation of an orphan G-protein-coupled receptor, GPR81. J. Biol. Chem.
2009, 284, 2811–2822. [CrossRef] [PubMed]
74. Haas, R.; Cucchi, D.; Smith, J.; Pucino, V.; Macdougall, C.E.; Mauro, C. Intermediates of Metabolism: From
Bystanders to Signalling Molecules. Trends Biochem. Sci. 2016, 41, 460–471. [CrossRef] [PubMed]
75. Jha, A.K.; Huang, S.C.; Sergushichev, A.; Lampropoulou, V.; Ivanova, Y.; Loginicheva, E.; Chmielewski, K.;
Stewart, K.M.; Ashall, J.; Everts, B.; et al. Network integration of parallel metabolic and transcriptional data
reveals metabolic modules that regulate macrophage polarization. Immunity 2015, 42, 419–430. [CrossRef]
[PubMed]
76. Bao, X.R.; Ong, S.E.; Goldberger, O.; Peng, J.; Sharma, R.; Thompson, D.A.; Vafai, S.B.; Cox, A.G.; Marutani, E.;
Ichinose, F.; et al. Mitochondrial dysfunction remodels one-carbon metabolism in human cells. eLife 2016, 5,
E10575. [CrossRef] [PubMed]
77. Cuyàs, E.; Fernández-Arroyo, S.; Corominas-Faja, B.; Rodríguez-Gallego, E.; Bosch-Barrera, J.;
Martin-Castillo, B.; de Llorens, R.; Joven, J.; Menendez, J.A. Oncometabolic mutation IDH1 R132H confers a
metformin-hypersensitive phenotype. Oncotarget 2015, 6, 12279–12296. [CrossRef] [PubMed]
78. Katada, S.; Imhof, A.; Sassone-Corsi, P. Connecting threads: Epigenetics and metabolism. Cell 2012, 148,
24–28. [CrossRef] [PubMed]
79. Huypens, P.; Sass, S.; Wu, M.; Dyckhoff, D.; Tschöp, M.; Theis, F.; Marschall, S.; Hrabe de Angelis, M.;
Beckers, J. Epigenetic germline inheritance of diet-induced obesity and insulin resistance. Nat. Genet. 2016,
48, 497–499. [CrossRef] [PubMed]
80. Öst, A.; Lempradl, A.; Casas, E.; Weigert, M.; Tiko, T.; Deniz, M.; Pantano, L.; Boenisch, U.; Itskow, P.M.;
Stoeckius, M.; et al. Paternal diet defines offspring chromatin state and intergenerational obesity. Cell 2014,
159, 1352–1364. [CrossRef] [PubMed]
81. Foster, G.D.; Wyatt, H.R.; Hill, J.O.; Makris, A.P.; Rosenbaum, D.L.; Brill, C.; Stein, R.I.; Mohammed, B.S.;
Miller, B.; Rader, D.J.; et al. Weight and metabolic outcomes after 2 years on a low-carbohydrate versus
low-fat diet: A randomized trial. Ann. Intern. Med. 2010, 153, 147–157. [CrossRef] [PubMed]
Nutrients 2017, 9, 121 16 of 19
82. Painter, R.C.; Roseboom, T.J.; Bleker, O.P. Prenatal exposure to the Dutch famine and disease in later life:
An overview. Reprod. Toxicol. 2005, 20, 345–352. [CrossRef] [PubMed]
83. Li, Y.; He, Y.; Qi, L.; Jaddoe, V.W.; Feskens, E.J.; Yang, X.; Ma, G.; Hu, F.N. Exposure to the Chinese famine
in early life and the risk of hyperglycemia and type 2 diabetes in adulthood. Diabetes 2010, 59, 2400–2406.
[CrossRef] [PubMed]
84. Stanner, S.A.; Bulmer, K.; Andrès, C.; Lantseva, O.E.; Borodina, V.; Poteen, V.V.; Yudkin, J.S. Does malnutrition
in utero determine diabetes and coronary heart disease in adulthood? Results from the Leningrad siege
study, a cross sectional study. BMJ 1997, 315, 1342–1348. [CrossRef] [PubMed]
85. Finer, S.; Saravanan, P.; Hitman, G.; Yajnik, C. The role of the one-carbon cycle in the developmental origins
of Type 2 diabetes and obesity. Diabet. Med. 2014, 31, 263–272. [CrossRef] [PubMed]
86. Tobi, E.W.; Goeman, J.J.; Monajemi, R.; Gu, H.; Putter, H.; Zhang, Y.; Slieker, R.C.; Stok, A.P.; Thijssen, P.E.;
Müller, F.; et al. DNA methylation signatures link prenatal famine exposure to growth and metabolism.
Nat. Commun. 2014, 5, 5592. [CrossRef] [PubMed]
87. Hernández-Aguilera, A.; Fernández-Arroyo, S.; Cuyàs, E.; Luciano-Mateo, F.; Cabre, N.; Camps, J.;
Lopez-Miranda, J.; Menendez, J.A.; Joven, J. Epigenetics and nutrition-related epidemics of metabolic
diseases: Current perspectives and challenges. Food. Chem. Toxicol. 2016, 96, 191–204. [CrossRef] [PubMed]
88. Klosin, A.; Lehner, B. Mechanisms, timescales and principles of trans-generational epigenetic inheritance in
animals. Curr. Opin. Genet. Dev. 2016, 36, 41–49. [CrossRef] [PubMed]
89. Fontana, L.; Partridge, L. Promoting health and longevity through diet: From model organisms to humans.
Cell 2015, 161, 106–118. [CrossRef] [PubMed]
90. Martinez-Outschoorn, U.E.; Peiris-Pagés, M.; Pestell, R.G.; Sotgia, F.; Lisanti, M.P. Cancer metabolism:
A therapeutic perspective. Nat. Rev. Clin. Oncol. 2016. [CrossRef] [PubMed]
91. Maddocks, O.D.; Labuschagne, C.F.; Adams, P.D.; Vousden, K.H. Serine metabolism supports the methionine
cycle and DNA/RNA methylation through de novo ATP Synthesis in Cancer Cells. Mol. Cell 2016, 61,
210–221. [CrossRef] [PubMed]
92. Mentch, S.J.; Locasale, J.W. One-carbon metabolism and epigenetics: Understanding the specificity. Ann. N.
Y. Acad. Sci. 2016, 1363, 91–98. [CrossRef] [PubMed]
93. Dawson, M.A.; Kouzarides, T. Cancer epigenetics: From mechanism to therapy. Cell 2012, 150, 12–27.
[CrossRef] [PubMed]
94. Fang, D.; Gan, H.; Lee, J.H.; Han, J.; Wang, Z.; Riester, S.M.; Jin, L.; Chen, J.; Zhou, H.; Wang, J.; et al.
The histone H3.3K36M mutation reprograms the epigenome of chondroblastomas. Science 2016, 352,
1344–1348. [CrossRef] [PubMed]
95. Orgeron, M.L.; Stone, K.P.; Wanders, D.; Cortez, C.C.; Van, N.T.; Gettys, T.W. The impact of dietary methionine
restriction on biomarkers of metabolic health. Prog. Mol. Biol. Transl. Sci. 2014, 121, 351–376. [PubMed]
96. Cuyàs, E.; Fernández-Arroyo, S.; Joven, J.; Menendez, J.A. Metformin targets histone acetylation in
cancer-prone epithelial cells. Cell Cycle 2016, 15, 3413–3416. [CrossRef] [PubMed]
97. Farber, S.; Diamond, L.K. Temporary remissions in acute leukemia in children produced by folic acid
antagonist, 4-aminopteroyl-glutamic acid. N. Engl. J. Med. 1948, 238, 787–793. [CrossRef] [PubMed]
98. Tannenbaum, A. The dependence of tumor formation on the composition of the calorie- restricted diet as
well as on the degree of restriction. Cancer Res. 1945, 5, 616–625.
99. Heckman-Stoddard, B.M.; Gandini, S.; Puntoni, M.; Dunn, B.K.; De Censi, A.; Szabo, E. Repurposing old
drugs to chemoprevention: The case of metformin. Semin. Oncol. 2016, 43, 123–133. [CrossRef] [PubMed]
100. Marini, C.; Bianchi, G.; Buschiazzo, A.; Ravera, S.; Martella, R.; Bottoni, G.; Petretto, A.; Emionite, L.;
Monteverde, E.; Capitanio, S.; et al. Divergent targets of glycolysis and oxidative phosphorylation result in
additive effects of metformin and starvation in colon and breast cancer. Sci. Rep. 2016, 6, 19569. [CrossRef]
[PubMed]
101. Menendez, J.A.; Oliveras-Ferraros, C.; Cufí, S.; Corominas-Faja, B.; Joven, J.; Martin-Castillo, B.
Vazquez-Martin, A. Metformin is synthetically lethal with glucose withdrawal in cancer cells. Cell Cycle
2012, 11, 2782–2792. [CrossRef] [PubMed]
102. Van Wijk, J.P.; de Koning, E.J.; Cabezas, M.C.; op’t Roodt, J.; Joven, J.; Rabelink, T.J.; Hoepelman, A.I.
Comparison of rosiglitazone and metformin for treating HIV lipodystrophy: A randomized trial.
Ann. Intern. Med. 2005, 143, 337–346. [CrossRef] [PubMed]
Nutrients 2017, 9, 121 17 of 19
103. Hawley, S.A.; Ross, F.A.; Chevtzoff, C.; Green, K.A.; Evans, A.; Fogarty, S.; Towler, M.C.; Brown, L.J.;
Ogunbayo, O.A.; Evans, A.M.; et al. Use of cells expressing gamma subunit variants to identify diverse
mechanisms of AMPK activation. Cell Metab. 2010, 11, 554–565. [CrossRef] [PubMed]
104. Zhou, G.; Myers, R.; Li, Y.; Chen, Y.; Shen, X.; Fenyk-Melody, J.; Wu, M.; Ventre, J.; Doebber, T.; Fujii, N.; et al.
Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Investig. 2001, 108,
1167–1174. [CrossRef] [PubMed]
105. Madiraju, A.K.; Erion, D.M.; Rahimi, Y.; Zhang, X.M.; Braddock, D.T.; Albright, R.A.; Prigaro, B.J.; Wood, J.L.;
Bhanot, S.; MacDonald, M.J.; et al. Metformin suppresses gluconeogenesis by inhibiting mitochondrial
glycerophosphate dehydrogenase. Nature 2014, 510, 542–546. [CrossRef] [PubMed]
106. Menendez, J.A.; Cufí, S.; Oliveras-Ferraros, C.; Martin-Castillo, B.; Joven, J.; Vellon, L.; Vazquez-Martín, A.
Metformin and the ATM DNA damage response (DDR): Accelerating the onset of stress-induced senescence
to boost protection against cancer. Aging 2011, 3, 1063–1077. [CrossRef] [PubMed]
107. Menendez, J.A.; Joven, J. One-carbon metabolism: An aging-cancer crossroad for the gerosuppressant
metformin. Aging 2012, 4, 894–898. [CrossRef] [PubMed]
108. Menendez, J.A.; Martin-Castillo, B.; Joven, J. Metformin and cancer: Quo vadis et cui bono? Oncotarget 2016.
[CrossRef] [PubMed]
109. Municio, C.; Soler-Palacios, B.; Estrada-Capetillo, L.; Benguria, A.; Dopazo, A.; García-Lorenzo, E.;
Fernández-Arroyo, S.; Joven, J.; Miranda-Carús, M.E.; González-Álvaro, I.; et al. Methotrexate selectively
targets human proinflammatory macrophages through a thymidylate synthase/p53 axis. Ann. Rheum. Dis.
2016, 75, 2157–2165. [CrossRef] [PubMed]
110. Rena, G.; Pearson, E.R.; Sakamoto, K. Molecular mechanism of action of metformin: Old or new insights?
Diabetologia 2013, 56, 1898–1906. [CrossRef] [PubMed]
111. Shu, Y.; Sheardown, S.A.; Brown, C.; Owen, R.P.; Zhang, S.; Castro, R.A.; Ianculescu, A.G.; Yue, L.; Lo, J.C.;
Burchard, E.G.; et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin
action. J. Clin. Investig. 2007, 117, 1422–1431. [CrossRef] [PubMed]
112. Dujic, T.; Zhou, K.; Donnelly, L.A.; Tavendale, R.; Palmer, C.N.; Pearson, E.R. Association of organic cation
transporter 1 with intolerance to metformin in type 2 diabetes: A GoDARTS study. Diabetes 2015, 64,
1786–1793. [CrossRef] [PubMed]
113. Dujic, T.; Causevic, A.; Bego, T.; Malenica, M.; Velija-Asimi, Z.; Pearson, E.R.; Semiz, S. Organic cation
transporter 1 variants and gastrointestinal side effects of metformin in patients with type 2 diabetes.
Diabet. Med. 2016, 33, 511–514. [CrossRef] [PubMed]
114. Zhou, K.; Bellenguez, C.; Spencer, C.C.; Bennett, A.J.; Coleman, R.L.; Tavendale, R.; Hawley, S.A.;
Donnelly, L.A.; Schofield, C.; Groves, C.J.; et al. Common variants near ATM are associated with glycemic
response to metformin in type 2 diabetes. Nat. Genet. 2011, 43, 117–120. [CrossRef] [PubMed]
115. Scheen, A.J. Personalising metformin therapy: A clinician’s perspective. Lancet Diabetes Endocrinol. 2014, 2,
442–444. [CrossRef]
116. Ter Borg, S.; de Groot, L.C.; Mijnarends, D.M.; de Vries, J.H.; Verlaan, S.; Meijboom, S.; Luiking, Y.C.;
Schols, J.M. Differences in Nutrient Intake and Biochemical Nutrient Status Between Sarcopenic and
Nonsarcopenic Older Adults-Results From the Maastricht Sarcopenia Study. J. Am. Med. Dir. Assoc.
2016, 17, 393–401. [CrossRef] [PubMed]
117. Malaguarnera, G.; Gagliano, C.; Salomone, S.; Giordano, M.; Bucolo, C.; Pappalardo, A.; Drago, F.; Caraci, F.;
Avitabile, T.; Motta, M. Folate status in type 2 diabetic patients with and without retinopathy. Clin. Ophthalmol.
2015, 9, 1437–1442. [CrossRef] [PubMed]
118. Mudryj, A.N.; de Groh, M.; Aukema, H.M.; Yu, N. Folate intakes from diet and supplements may place
certain Canadians at risk for folic acid toxicity. Br. J. Nutr. 2016, 116, 1236–1245. [CrossRef] [PubMed]
119. Danenberg, P.V.; Gustavsson, B.; Johnston, P.; Lindberg, P.; Moser, R.; Odin, E.; Peters, G.J.; Petrelli, N. Folates
as adjuvants to anticancer agents: Chemical rationale and mechanism of action. Crit. Rev. Oncol. Hematol.
2016, 106, 118–131. [CrossRef] [PubMed]
120. Yajnik, C.S.; Deshpande, S.S.; Jackson, A.A.; Refsum, H.; Rao, S.; Fisher, D.J.; Bhat, D.S.; Naik, S.S.; Coyaki, K.J.;
Joglekar, C.V.; et al. Vitamin B12 and folate concentrations during pregnancy and insulin resistance in the
offspring: The Pune Maternal Nutrition Study. Diabetologia 2008, 51, 29–38. [CrossRef] [PubMed]
Nutrients 2017, 9, 121 18 of 19
121. Scott, J.M.; Weir, D.G. The methyl folate trap. A physiological response in man to prevent methyl group
deficiency in kwashiorkor (methionine deficiency) and an explanation for folic-acid induced exacerbation of
subacute combined degeneration in pernicious anaemia. Lancet 1981, 2, 337–340. [CrossRef]
122. Stowers, J.M.; Smith, O.A. Vitamin B12 and metformin. BMJ 1971, 3, 246–247. [CrossRef] [PubMed]
123. Ting, R.Z.; Szeto, C.C.; Chan, M.H.; Ma, K.K.; Chow, K.M. Risk factors of vitamin B12 deficiency in patients
receiving metformin. Arch. Intern. Med. 2006, 166, 1975–1979. [CrossRef] [PubMed]
124. Liu, Q.; Li, S.; Quan, H.; Li, J. Vitamin B12 status in metformin treated patients: Systematic review. PLoS ONE
2014, 9, E100379. [CrossRef] [PubMed]
125. Obeid, R.; Jung, J.; Falk, J.; Herrmann, W.; Geisel, J.; Friesenhahn-Ochs, B.; Lammerts, F.; Fassbender, K.;
Kostopoulos, P. Serum vitamin B12 not reflecting vitamin B12 status in patients with type 2 diabetes. Biochimie
2013, 95, 1056–1061. [CrossRef] [PubMed]
126. Greibe, E.; Trolle, B.; Bor, M.V.; Lauszus, F.F.; Nexo, E. Metformin lowers serum cobalamin without changing
other markers of cobalamin status: A study on women with polycystic ovary syndrome. Nutrients 2013, 5,
2475–2482. [CrossRef] [PubMed]
127. Leung, S.; Mattman, A.; Snyder, F.; Kassam, R.; Meneilly, G.; Nexo, E. Metformin induces reductions in
plasma cobalamin and haptocorrin bound cobalamin levels in elderly diabetic patients. Clin. Biochem. 2010,
43, 759–760. [CrossRef] [PubMed]
128. Ahmed, M.A. Metformin and Vitamin B12 Deficiency: Where Do We Stand? J. Pharm. Pharm. Sci. 2016, 19,
382–398. [CrossRef] [PubMed]
129. DeFronzo, R.; Fleming, G.A.; Chen, K.; Bicsak, T.A. Metformin-associated lactic acidosis: Current perspectives
on causes and risk. Metabolism 2016, 65, 20–29. [CrossRef] [PubMed]
130. Pernicova, I.; Korbonits, M. Metformin—Mode of action and clinical implications for diabetes and cancer.
Nat. Rev. Endocrinol. 2014, 10, 143–156. [CrossRef] [PubMed]
131. De Jager, J.; Kooy, A.; Lehert, P.; Wulffelé, M.G.; van der Kolk, J.; Bets, D.; Verburg, J.; Donker, A.J.;
Stehouwer, C.D. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin
B-12 deficiency: Randomised placebo controlled trial. BMJ 2010, 340, c2181. [CrossRef] [PubMed]
132. McCreight, L.J.; Bailey, C.J.; Pearson, E.R. Metformin and the gastrointestinal tract. Diabetologia 2016, 59,
426–435. [CrossRef] [PubMed]
133. Wu, T.; Thazhath, S.S.; Bound, M.J.; Jones, K.L.; Horowitz, M.; Rayner, C.K. Mechanism of increase in plasma
intact GLP-1 by metformin in type 2 diabetes: Stimulation of GLP-1 secretion or reduction in plasma DPP-4
activity? Diabetes Res. Clin. Pract. 2014, 106, e3–e6. [CrossRef] [PubMed]
134. Yee, S.W.; Lin, L.; Merski, M.; Keiser, M.J.; Gupta, A.; Zhang, Y.; Chien, H.C.; Shoichet, B.K.; Giacomini, K.M.
Prediction and validation of enzyme and transporter off-targets for metformin. J. Pharmacokinet. Pharmacodyn.
2015, 42, 463–475. [CrossRef] [PubMed]
135. Scarpello, J.H.; Hodgson, E.; Howlett, H.C. Effect of metformin on bile salt circulation and intestinal motility
in type 2 diabetes mellitus. Diabet. Med. 1998, 15, 651–656. [CrossRef]
136. Forslund, K.; Hildebrand, F.; Nielsen, T.; Falony, G.; Le Chatelier, E.; Sunagawa, S.; Prifti, E.; Vieira-Silva, S.;
Gudmundsdottir, V.; Krogh Pedersen, H.; et al. Disentangling type 2 diabetes and metformin treatment
signatures in the human gut microbiota. Nature 2015, 528, 262–266. [CrossRef] [PubMed]
137. Burton, J.H.; Johnson, M.; Johnson, J.; Hsia, D.S.; Greenway, F.L.; Heiman, M.L. Addition of a gastrointestinal
microbiome modulator to metformin improves metformin tolerance and fasting glucose levels. J. Diabetes
Sci. Technol. 2015, 9, 808–814. [CrossRef] [PubMed]
138. Mardinoglu, A.; Boren, J.; Smith, U. Confounding Effects of Metformin on the Human Gut Microbiome in
Type 2 Diabetes. Cell Metab. 2016, 23, 10–12. [CrossRef] [PubMed]
139. Bhalerao, K.D.; Lee, S.C.; Soboyejo, W.O.; Soboyejo, A.B. A folic acid-based functionalized surface for
biosensor systems. J. Mater. Sci. Mater. Med. 2007, 18, 3–8. [CrossRef] [PubMed]
140. Armbruster, D.A.; Alexander, D.B. Sample to sample carryover: A source of analytical laboratory error
and its relevance to integrated clinical chemistry/immunoassay systems. Clin. Chim. Acta 2006, 373, 37–43.
[CrossRef] [PubMed]
141. Bertran, N.; Camps, J.; Fernández-Ballart, J.; Murphy, M.M.; Arija, V.; Ferré, N.; Tous, M.; Joven, J. Evaluation
of a high-sensitivity turbidimetric immunoassay for serum C-reactive protein: Application to the study of
longitudinal changes throughout normal pregnancy. Clin. Chem. Lab. Med. 2005, 43, 308–313. [CrossRef]
[PubMed]
Nutrients 2017, 9, 121 19 of 19
142. Wainwright, P.; Narayanan, S.; Cook, P. False-normal vitamin B12 results in a patient with pernicious
anaemia. Clin. Biochem. 2015, 48, 1366–1377. [CrossRef] [PubMed]
143. Harrington, D.J. Holotranscobalamin: In the middle of difficultly lies opportunity. Clin. Chem. Lab. Med.
2016, 54, 1407–1409. [CrossRef] [PubMed]
144. Kancherla, V.; Garn, J.V.; Zakai, N.A.; Williamson, R.S.; Cashion, W.T.; Odewole, O.; Judd, S.E.; Oakley, G.P., Jr.
Multivitamin Use and Serum Vitamin B12 Concentrations in Older-Adult Metformin Users in REGARDS,
2003–2007. PLoS ONE 2016, 11, E0160802. [CrossRef] [PubMed]
145. Russo, G.T.; Giandalia, A.; Romeo, E.L.; Scarcella, C.; Gambadoro, N.; Zingale, R.; Forte, F.; Perdichizzi, G.;
Alibrandi, A.; Cucinotta, D. Diabetic neuropathy is not associated with homocysteine, folate, vitamin B12
levels, and MTHFR C677T mutation in type 2 diabetic outpatients taking metformin. J. Endocrinol. Investig.
2016, 39, 305–314. [CrossRef] [PubMed]
146. Bird, J.K.; Ronnenberg, A.G.; Choi, S.W.; Du, F.; Mason, J.B.; Liu, Z. Obesity is associated with increased red
blood cell folate despite lower dietary intakes and serum concentrations. J. Nutr. 2015, 145, 79–86. [CrossRef]
[PubMed]
147. Denimal, D.; Brindisi, M.C.; Lemaire, S.; Duvillard, L. Assessment of Folate Status in Obese Patients: Should
We Measure Folate in Serum or in Red Blood Cells? Obes. Surg. 2016. [CrossRef] [PubMed]
148. Yetley, E.A.; Johnson, C.L. Folate and vitamin B-12 biomarkers in NHANES: History of their measurement
and use. Am. J. Clin. Nutr. 2011, 94, 322S–331S. [CrossRef] [PubMed]
149. Zhang, Q.; Li, S.; Li, L.; Li, Q.; Ren, K.; Sun, X.; Li, J. Metformin treatment and homocysteine: A systematic
review and meta-analysis of randomized controlled trials. Nutrients 2016, 8, 798. [CrossRef] [PubMed]
150. Pfeiffer, C.M.; Sternberg, M.R.; Fazili, Z.; Lacher, D.A.; Zhang, M.; Johnson, C.L.; Hamner, H.C.; Bailey, R.L.;
Rader, J.I.; Yamini, S. Folate status and concentrations of serum folate forms in the US population: National
Health and Nutrition Examination Survey 2011–2012. Br. J. Nutr. 2015, 113, 1965–1977. [CrossRef] [PubMed]
151. Dominguez-Salas, P.; Moore, S.E.; Cole, D.; da Costa, K.A.; Cox, S.E.; Dyer, R.A.; Fuldord, A.J.; Innis, S.M.;
Waterland, R.A.; Zeisel„ S.H.; et al. DNA methylation potential: Dietary intake and blood concentrations
of one-carbon metabolites and cofactors in rural African women. Am. J. Clin. Nutr. 2013, 97, 1217–1227.
[CrossRef] [PubMed]
152. Kühnen, P.; Handke, D.; Waterland, R.A.; Hennig, B.J.; Silver, M.; Fulford, A.J.; Dominguez-Salas, P.;
Moore, S.E.; Prentice, A.M.; Spranger, J.; et al. Interindividual Variation in DNA Methylation at a Putative
POMC Metastable Epiallele Is Associated with Obesity. Cell Metab. 2016, 24, 502–509. [CrossRef]
153. Eicher-Miller, H.A.; Fulgoni, V.L.; Keast, D.R. Processed Food Contributions to Energy and Nutrient Intake
Differ among US Children by Race/Ethnicity. Nutrients 2015, 7, 10076–10088. [CrossRef] [PubMed]
154. Colditz, G.A. Overview of the epidemiology methods and applications: Strengths and limitations of
observational study designs. Crit. Rev. Food. Sci. Nutr. 2010, 50 (Suppl. 1), 10–12. [CrossRef] [PubMed]
155. Fernández-Arroyo, S.; Cuyàs, E.; Bosch-Barrera, J.; Alarcón, T.; Joven, J.; Menendez, J.A. Activation of the
methylation cycle in cells reprogrammed into a stem cell-like state. Oncoscience 2016, 2, 958–967. [PubMed]
156. Riera-Borrull, M.; Rodríguez-Gallego, E.; Hernández-Aguilera, A.; Luciano, F.; Ras, R.; Cuyàs, E.; Camps, J.;
Segura-Carretero, A.; Menendez, J.A.; Joven, J.; et al. Exploring the Process of Energy Generation in
Pathophysiology by Targeted Metabolomics: Performance of a Simple and Quantitative Method. J. Am. Soc.
Mass. Spectrom. 2016, 27, 168–177. [CrossRef] [PubMed]
157. Liu, X.; Romero, I.L.; Litchfield, L.M.; Lengyel, E.; Locasale, J.W. Metformin Targets Central Carbon
Metabolism and Reveals Mitochondrial Requirements in Human Cancers. Cell Metab. 2016. [CrossRef]
[PubMed]
© 2017 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
